Oxsm-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Oxsm-KO 基因敲除小鼠

产品编号

S-KO-13514

品系全称

C57BL/6JCya-Oxsmem1/Cya

品系背景

C57BL/6JCya

品系编号

KOCMP-71147-Oxsm-B6J-VA

品系状态

使用本品系发表的文献需注明: Oxsm-KO 基因敲除小鼠 mice (Strain S-KO-13514) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量

基本信息

基因研究概述

质控标准

基因
基因全称
3-oxoacyl-ACP synthase, mitochondrial
基因别称
4933425A18Rik
染色体号
Chr 14 (Mouse)
转录本 ID
NCBI: NM_027695 | Ensembl: ENSMUST00000022311
修饰方式
全身性基因敲除
靶向范围
Exon 2~3
敲除长度
~2.4 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
OXSM,也称为线粒体3-氧酰-ACP合成酶,是一种重要的线粒体脂肪酸合成酶。它在线粒体中催化脂肪酸合成的第一步反应,将丙二酰辅酶A和乙酰辅酶A结合生成3-氧酰-ACP,这是脂肪酸合成的重要起始物质。OXSM的表达和活性受到多种因素的调控,包括细胞能量状态、代谢途径和线粒体功能等。OXSM在多种生物学过程中发挥重要作用,包括细胞生长、发育、代谢和疾病发生。

OXSM在多种癌症中发挥重要作用。在结直肠癌中,OXSM的表达与患者生存率和肿瘤微环境密切相关。OXSM可以调节肿瘤微环境,影响药物敏感性和免疫微环境[1]。在肝细胞癌中,OXSM的活性受到KAT8和PCK2的调控,从而影响肝细胞铁死亡的发生和发展[2]。在口腔鳞状细胞癌中,OXSM的表达与患者预后不良相关,CBFB转录因子可以调控OXSM的表达[3]。在膀胱癌中,OXSM是诊断模型的关键基因之一,其表达与免疫细胞浸润相关[4]。

OXSM在其他疾病中也发挥重要作用。在骨质疏松症中,OXSM是区分骨质疏松症样本和对照组的关键基因之一,其表达与免疫细胞浸润相关[5]。在脑胶质母细胞瘤中,hsa-miR-338-3p通过直接靶向OXSM基因,影响GBM细胞的生物发生和快速增殖[6]。在弥漫性大B细胞淋巴瘤中,OXSM是DRGs之一,可以预测患者预后[7]。在骨关节炎中,OXSM是区分早期和晚期骨关节炎的关键基因之一,其表达与免疫细胞浸润相关[8]。在溃疡性结肠炎中,OXSM是区分溃疡性结肠炎样本和对照组的关键基因之一,其表达与免疫细胞浸润相关[9]。在类风湿性关节炎中,OXSM是诊断模型的关键基因之一,其表达与免疫细胞浸润相关[10]。

综上所述,OXSM是一种重要的线粒体脂肪酸合成酶,在多种生物学过程中发挥重要作用,包括细胞生长、发育、代谢和疾病发生。OXSM在多种癌症和其他疾病中发挥重要作用,可以作为诊断和治疗的潜在靶点。深入研究OXSM的生物学功能和调控机制,有助于开发新的治疗策略,提高疾病的治疗效果。

参考文献:
1. Hu, Gunchu, Yao, Hongliang, Wei, Zuxing, Luo, Xiong, Guo, Zhushu. 2023. A bioinformatics approach to identify a disulfidptosis-related gene signature for prognostic implication in colon adenocarcinoma. In Scientific reports, 13, 12403. doi:10.1038/s41598-023-39563-y. https://pubmed.ncbi.nlm.nih.gov/37524774/
2. Yuan, Jingsheng, Yang, Mingyang, Wu, Zhenru, Yang, Jiayin, Yang, Jian. 2025. The Lactate-Primed KAT8‒PCK2 Axis Exacerbates Hepatic Ferroptosis During Ischemia/Reperfusion Injury by Reprogramming OXSM-Dependent Mitochondrial Fatty Acid Synthesis. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), , e2414141. doi:10.1002/advs.202414141. https://pubmed.ncbi.nlm.nih.gov/39853940/
3. Zhang, Liru, Zhao, Shuangling, Liu, Yuanhang, Lv, Feifei, Geng, Xixue. 2022. Identification and validation of transcription factor-driven enhancers of genes related to lipid metabolism in metastatic oral squamous cell carcinomas. In BMC oral health, 22, 126. doi:10.1186/s12903-022-02157-7. https://pubmed.ncbi.nlm.nih.gov/35428233/
4. Li, Jian, Wang, Zhiyong, Wang, Tianen. 2024. Machine-learning prediction of a novel diagnostic model using mitochondria-related genes for patients with bladder cancer. In Scientific reports, 14, 9282. doi:10.1038/s41598-024-60068-9. https://pubmed.ncbi.nlm.nih.gov/38654047/
5. Zhang, Peng, Li, Bing, Chen, Honglin, Jiang, Xiaobing, Cui, Jianchao. 2024. RNA sequencing-based approaches to identifying disulfidptosis-related diagnostic clusters and immune landscapes in osteoporosis. In Aging, 16, 8198-8216. doi:10.18632/aging.205813. https://pubmed.ncbi.nlm.nih.gov/38738994/
6. Wang, Wen-Yi, Lu, Wei-Cheng. 2020. Reduced Expression of hsa-miR-338-3p Contributes to the Development of Glioma Cells by Targeting Mitochondrial 3-Oxoacyl-ACP Synthase (OXSM) in Glioblastoma (GBM). In OncoTargets and therapy, 13, 9513-9523. doi:10.2147/OTT.S262873. https://pubmed.ncbi.nlm.nih.gov/33061435/
7. Wang, Yu, Tsukamoto, Yoshiyuki, Hori, Mitsuo, Iha, Hidekatsu. 2024. Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL). In International journal of molecular sciences, 25, . doi:10.3390/ijms25137156. https://pubmed.ncbi.nlm.nih.gov/39000261/
8. Hu, Kaibo, Ou, Yanghuan, Xiao, Leyang, Li, Ting, Hao, Liang. 2024. Identification and Construction of a Disulfidptosis-Mediated Diagnostic Model and Associated Immune Microenvironment of Osteoarthritis from the Perspective of PPPM. In Journal of inflammation research, 17, 3753-3770. doi:10.2147/JIR.S462179. https://pubmed.ncbi.nlm.nih.gov/38882183/
9. Yang, Lichao, Yuan, Lianwen, Liu, Ganglei. 2024. Comprehensive evaluation of disulfidptosis in intestinal immunity and biologic therapy response in Ulcerative Colitis. In Heliyon, 10, e34516. doi:10.1016/j.heliyon.2024.e34516. https://pubmed.ncbi.nlm.nih.gov/39148969/
10. Xu, Bin, Zhang, Hai Long, Shen, Bo, Li, Xiao Duo, Guo, Qiong. 2025. Identification biomarkers and therapeutic targets of disulfidptosis-related in rheumatoid arthritis via bioinformatics, molecular dynamics simulation, and experimental validation. In Scientific reports, 15, 8779. doi:10.1038/s41598-025-93656-4. https://pubmed.ncbi.nlm.nih.gov/40082645/